Orphan drug achieves success in Phase III trial

Article

Novagali Pharma has reported positive results from a Phase III clinical study investigating the use of its drug candidate, Vekacia, as a treatment for paediatric Vernal Keratoconjunctivitis (VKC).

Novagali Pharma has reported positive results from a Phase III clinical study investigating the use of its drug candidate, Vekacia, as a treatment for paediatric Vernal Keratoconjunctivitis (VKC).

The study, led by Professor David Ben Ezra of the Hadassah Hebrew University Hospital, Jerusalem, Israel, showed that both symptoms and signs of VKC improved in patients receiving Vekacia.

Vekacia is a topical Cyclosporine A cationic emulsion, which enables efficient drug absorption in tissues of the eye. Novagali received EMEA orphan drug designation for Vekacia in the treatment of VKC in March 2006.

Based upon the success of the study, the company plans to file for European Marketing Authorization in the middle of 2007.

In other news, Novagali has also entered into a strategic collaboration with biopharmaceutical firm Topigen Pharmaceuticals. Under the terms of the agreement, Novagali will receive exclusive worldwide rights to develop and commercialize an ophthalmic product based on Topigen's multi-targeted, RNA-targeting platform technology for the treatment and prevention of allergic eye diseases.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.